13F Holdings
中文EN

FTH Faeth Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1829802 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-775.6%
TTM EPS YoY-17.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-229.6%
ROA-204.7%
ROIC (approx.)-214.2%
Asset turnover—

Leverage & solvency

Liabilities / assets6.2%
Debt / equity0.00x
Current ratio16.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-162.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
SG&A expense$11.33M$13.04M$18.77M$19.80M$15.82M
Operating income-$22.29M-$32.61M-$37.06M-$50.19M-$37.48M
Interest expense$32,000$90,000$144,000$219,000$670,000
Pretax income-$21.09M-$30.16M———
Income tax$0$0———
Net income-$21.09M-$30.16M-$34.10M-$48.59M-$36.79M
EBITDA-$22.17M-$32.06M-$36.49M-$49.57M-$36.80M
EPS (basic)-16.72-24.01-1.22-1.58-1.33
EPS (diluted)-16.72-24.01-1.22-1.58-1.33
Weighted avg. shares (diluted)1.26M1.26M27.95M30.70M27.71M
Balance sheet
Cash & equivalents$8.67M$9.99M$13.01M$17.80M$7.16M
Short-term investments$12.52M$31.34M$52.75M$89.32M$140.46M
Current assets$21.51M$41.93M$67.25M$108.59M$148.54M
PP&E, net$82,000$417,000$1.17M$2.05M$4.64M
Total assets$22.90M$45.36M$74.37M$118.38M$153.22M
Current liabilities$4.25M$5.45M$5.64M$9.07M$4.89M
Total liabilities$4.31M$6.97M$9.48M$14.97M$6.71M
Shareholders' equity$18.59M$38.39M$64.89M$103.41M$146.51M
Shares outstanding1.26M1.26M25.03M30.76M30.61M
Cash flow statement
Operating cash flow-$20.45M-$24.67M-$32.02M-$39.03M-$30.26M
Capital expenditure$16,000$146,000$180,000$321,000$2.03M
Free cash flow-$20.47M-$24.82M-$32.20M-$39.35M-$32.28M
Investing cash flow$19.77M$22.44M$38.41M$49.95M-$143.12M
Financing cash flow-$645,000-$787,000-$11.17M-$287,000$163.94M
Depreciation & amortization$122,000$551,000$571,000$614,000$685,000
Stock-based compensation$1.27M$3.13M$4.45M$5.81M$5.66M
Share buybacks——$10.38M——

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.